The global dementia treatment market size is anticipated to reach USD 28.11 billion by 2030, registering a CAGR of 7.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing patient base of dementia, introduction of novel drugs, and increasing involvement of market players and research institutes to develop effective treatment for the disease are some of key factors driving market growth. According to the Cross River Therapy data published in September 2023, the prevalence of Alzheimer’s disease (AD) in the UK is around 42.70 cases per 100,000 people, which makes it the country with the second-greatest number of cases per capita.

Increasing favorable initiatives undertaken by government and non-government bodies to support the awareness campaign and research activities to develop novel therapies for dementia treatment are anticipated to fuel market growth. For instance, in February 2022, McGill University’s Dementia Education Program initiated 15 projects funded by the Public Health Agency of Canada to increase awareness about the disease. The Dementia Community Investment (DCI) is going to invest USD 758,430 to support the University’s Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning to spread awareness among caregivers.

Gather more insights about the market drivers, restrains and growth of the Global Dementia Treatment Market

Academic and research institutes are further involved in research activities to study different types of dementia and development of effective therapeutics to reduce the overall disease burden. For instance, in February 2024, researchers at the University of Colorado Anschutz Medical Campus found that Mdm2 protein with an investigational cancer drug, nutlin, can prevent the destruction of synapses and dendritic spines associated with Alzheimer’s disease. Moreover, in December 2023, A preclinical study from the Perelman School of Medicine at the University of Pennsylvania showed that a chaperone molecule formulated specific proteins that can reverse disease signs including aging brain and memory impairment.

Market players are collaborating with regional players and research institutions to increase their capabilities to develop effective and safe therapy for dementia. In February 2021, Exscientia and the University of Oxford tied up to develop therapies for Alzheimer’s disease. Moreover, Eisai Co., Ltd. and Biogen partnered to develop effective therapies for dementia earlier. These companies have jointly developed aducanumab and lecanemab. The companies are receiving market approvals for these drugs from key regulatory authorities across the globe.

Dementia Treatment Market Report Highlights

• The AD dementia segment dominated the indication segment market with a share of 60.11% in 2023 owing to a high prevalence of AD dementia and approved drugs

• The Lewy body dementia (LBD) segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the increasing incidence and severity of the disease

• The cholinesterase inhibitors segment held the largest share in 2023 owing to high prescription rate of oral and transdermal patches of these drugs

• The combination drug segment is projected to experience the fastest CAGR from 2024 to 2030 owing to increased effectiveness and adoption of combination drugs

• The injectables route of administration segment is anticipated to register the fastest CAGR from 2024 to 2030 owing to the introduction of biological drugs and the presence of promising injectable drugs in the pipeline

• North America dominated the global market in 2023 owing to factors, such as high disease prevalence, presence of strong market players, and better reimbursement policies in the region

List of Key Players in the Dementia Treatment Market

• Eisai Co., Ltd.
• Lilly
• Novartis AG
• Daiichi Sankyo Company, Ltd.
• AbbVie Inc.
• Lundbeck A/S
• Biogen
• Cipla Inc.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.

Order a free sample PDF of the Dementia Treatment Market Intelligence Study, published by Grand View Research.